Clinical trialPhase 2Unknown
Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas
Phase II Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas
- Outcome
- Outcome unknown
- Phase
- Phase 2
- Status
- Unknown
- Study type
- Interventional
- Start
- 1 August 2019
- Expected end
- 30 September 2021
- Enrollment
- 132 participants
- Sites
- 1
- Primary outcomes
- PFS
- Sponsor
- Other
- Results posted
- No
- Last update
- 8 July 2019
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 3
- BackgroundEfficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metast… DOI 10.1093/jjco/hyy063↗
- BackgroundIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. DOI 10.1056/nejmoa1304369↗
- BackgroundRandomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced a… DOI 10.1200/jco.2012.43.3680↗